Table 7.
Sensitivity GWAS Analysis After Removing Individuals with CVD Diagnoses in UKBB
| Lead SNP | IBS subtype | Discoverya IBS: 24,735 / IBS-M: 13,132 Control subjects: 77,149 |
UKBB ALL IBS: 22,745 / IBS-M: 12,335 Control subjects: 66,631 |
UKBB CVD- IBS: 16,752 / IBS-M: 8,955 Control subjects: 51,590 |
|||
|---|---|---|---|---|---|---|---|
| OR (95% CI) | P value | OR (95% CI) | P value | OR (95% CI) | P value | ||
| rs6899057 ADCY2 |
IBS | 1.07 (1.04–1.09) | 2.0E-08 | 1.08 (1.06–1.11) | 6.6E-08 | 1.08 (1.05–1.11) | 9.1E-06 |
| IBS-M | 1.09 (1.05–1.12) | 2.3E-08 | 1.07 (1.05–1.09) | 2.0E-08 | 1.06 (1.04–1.09) | 5.9E-06 | |
| rs2048419 CLDN23 / MFHAS1 |
IBS-M | 1.08 (1.05–1.11) | 4.4E-08 | 1.08 (1.06–1.11) | 3.2E-08 | 1.09 (1.06–1.12) | 3.2E-07 |
| rs2035380 BMAL1 |
IBS | 1.07 (1.04–1.09) | 3.1E-08 | 1.07 (1.05–1.10) | 4.0E-08 | 1.07 (1.04–1.10) | 1.1E-06 |
| rs9517497 DOCK9 |
IBS | 1.07 (1.04–1.09) | 2.3E-08 | 1.06 (1.04–1.09) | 3.1E-07 | 1.06 (1.04–1.09) | 8.1E-06 |
CI, confidence interval; CVD, cardiovascular diseases; GWAS, genome-wide association study; IBS, irritable bowel syndrome; IBS-C, irritable bowel syndrome constipation-predominant subtype; IBS-D, irritable bowel syndrome diarrhea-predominant subtype; IBS-M, irritable bowel syndrome mixed subtype; LL, Lifelines; OR, odds ratio; SD, standard deviation; SNP, single-nucleotide polymorphism; UKBB, UK Biobank.
a
Estimates from Rome III IBS GWAS meta-analyses (UKBB and LL).